An Open-Label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-Line Treatment of Subjects With Predominantly Non-Squamous Cell Stage IIIBwet/IV Non-Small Cell Lung Cancer.

Trial Profile

An Open-Label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-Line Treatment of Subjects With Predominantly Non-Squamous Cell Stage IIIBwet/IV Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2015

At a glance

  • Drugs Pazopanib (Primary) ; Pemetrexed (Primary) ; Cisplatin
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Oct 2015 Status changed from completed to discontinued according to results published in the Journal of Thoracic Oncology.
    • 07 Apr 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 07 Apr 2011 Status changed from active, no longer recruiting to completed. as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top